Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
AMGNAmgen Inc. | -1.45% | 14.49 |
AZNAstraZeneca PLC ADR | -0.84% | 29.39 |
GSKGlaxoSmithKline PLC ADR | -0.88% | 313.15 |
NVSNovartis AG ADR | -2.62% | 25.09 |
ABTAbbott Laboratories | -1.36% | 44.00 |
BMYBristol-Myers Squibb Co. | +0.14% | 27.82 |
JNJJohnson & Johnson | -0.35% | 20.42 |
LLYEli Lilly & Co. | -1.34% | 33.59 |
MRKMerck & Co. Inc. | -1.32% | 31.57 |
MYLMylan N.V. | -2.90% | 71.51 |
Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare,...
| Q4 2016 Estimate Trends | |
|---|---|
| Current: | $0.51 |
| 1 month ago: | $0.54 |
| 3 months ago: | $0.54 |
| Q1 2017 Estimate Trends | |
|---|---|
| Current: | $0.65 |
| 1 month ago: | $0.68 |
| 3 months ago: | $0.65 |
| Sep 2016 | 5-quarter trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | -37.77% | | ||||||||
| Sales or Revenue | 13.05 B | | ||||||||
| Sales or Revenue Growth | +7.93% | | ||||||||
| EBITDA | - | | ||||||||
| 2015 | 5-year trend | |||||||||
| Net Income Growth | -23.53% | | ||||||||
| Sales or Revenue | 48.85 B | | ||||||||
| Sales or Revenue Growth | -1.52% | | ||||||||
| EBITDA | +18.45 B | |